Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102114 · ClinicalTrials.gov registry record · Phase 3
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
A Phase 3 study, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT01102114 is a Phase 3 study that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 1,000 participants.
The verdict
NCT01102114, a Phase 3 study, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Interventions
- BIOLOGICAL Placebo Vaccine
- BIOLOGICAL NicVAX Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01102114
The ClinicalTrials.gov registry entry for NCT01102114 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabi Biopharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Vaccine is the first listed.
NCT01102114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01102114 about?
NCT01102114 is a clinical study titled "A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation". The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
What is the current status of trial NCT01102114?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2010-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01102114?
The interventions under investigation include: Placebo Vaccine (BIOLOGICAL), NicVAX Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01102114?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.